# Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

> **NCT07284459** · PHASE2 · RECRUITING · sponsor: **Contineum Therapeutics** · enrollment: 324 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** PIPE-791 Dose A
- **DRUG:** PIPE-791 Dose B
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07284459
- **Lead sponsor:** Contineum Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-08
- **Primary completion:** 2028-05
- **Final completion:** 2028-06
- **Target enrollment:** 324 (ESTIMATED)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07284459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07284459, "Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07284459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*